Profusa (PFSA) Preferred Stock Liabilities (2021 - 2025)
Profusa's (PFSA) quarterly Preferred Stock Liabilities came in at $1.3 million in Q2 2025, down 84.44% year-on-year from $8.6 million in Q2 2024, and down 32.89% quarter-over-quarter from $2.0 million in Q1 2025.
Profusa (PFSA) Preferred Stock Liabilities (2021 - 2025) Analysis & Trends
Profusa's Preferred Stock Liabilities history runs 5 years deep, the most recent figure standing at $1.3 million for Q2 2025.
- On a quarterly basis, Preferred Stock Liabilities fell 84.44% year-over-year to $1.3 million in Q2 2025; TTM through Jun 2025 was $1.3 million, a 84.44% decrease from a year earlier, with the FY2024 full-year figure at $13.7 million, up 48.08% from the prior year.
- Preferred Stock Liabilities eased to $1.3 million in Q2 2025 per PFSA's latest filing, from $2.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $193.5 million in Q4 2022 and bottomed at $1.3 million in Q2 2025.
- The 5-year median for Preferred Stock Liabilities is $10.4 million (2023), against an average of $69.6 million.
- Across the five-year window, Preferred Stock Liabilities plunged 95.22% in 2023 and soared 48.08% in 2024, its largest moves.
- Year by year, Preferred Stock Liabilities stood at $191.6 million in 2021, then advanced by 0.98% to $193.5 million in 2022, then plunged by 95.22% to $9.3 million in 2023, then surged by 48.08% to $13.7 million in 2024, then slumped by 90.29% to $1.3 million in 2025.
- Per Business Quant, the three latest PFSA Preferred Stock Liabilities figures stand at $1.3 million (Q2 2025), $2.0 million (Q1 2025), and $13.7 million (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Profusa | 23,566.40 | -351,433.60 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1.33 Mn |
| Mar 31, 2025 | 1.98 Mn |
| Dec 31, 2024 | 13.70 Mn |
| Sep 30, 2024 | 8.14 Mn |
| Jun 30, 2024 | 8.55 Mn |
| Mar 31, 2024 | 8.37 Mn |
| Dec 31, 2023 | 9.25 Mn |
| Sep 30, 2023 | 10.62 Mn |
| Jun 30, 2023 | 10.38 Mn |
| Mar 31, 2023 | 9.96 Mn |
| Dec 31, 2022 | 193.53 Mn |
| Sep 30, 2022 | 192.80 Mn |
| Jun 30, 2022 | 191.78 Mn |
| Mar 31, 2022 | 191.65 Mn |
| Dec 31, 2021 | 191.65 Mn |